Thumzup Media Corp. (NASDAQ: TZUP)

The QualityStocks Daily Newsletter would like to spotlight Thumzup Media Corp.(NASDAQ: TZUP).

Thumzup (NASDAQ: TZUP) , an emerging leader in social media branding and marketing solutions, is leveraging a business model that includes the powerful capabilities of its proprietary AdTech platform. Client companies can utilize the platform to efficiently create and manage social media advertising campaigns that motivate social media influencers as they generate and are paid for content that promotes products and services. "Our rapid growth to more than 700 advertisers up from around 200 this time last year is confirmation of the effectiveness of our disruptive advertising model," Thumzup CEO and Founder Robert Steele stated in a recent press release . "We are continuously growing and redefining how brands connect with consumers. By incentivizing engagement with direct cash rewards and harnessing a vast, untapped audience, we are delivering outsized value — and this is just the beginning." To view the full article, visit https://ibn.fm/6TVTH 

AI-related stocks have been hit after U.S. President Donald Trump announced broad tariffs on foreign goods, signaling potential trouble for the industry. Major players in artificial intelligence are currently pouring massive amounts of money into building data centers to power and train AI systems. According to analysts, the tariffs will push those already high costs even higher. AI servers and other datacenter gear are mostly imported. That includes essential infrastructure like cooling systems and power units, meaning the new tariffs will raise prices on many fronts. While chips themselves won't be taxed if shipped as individual units, most arrive inside assembled products like servers, which aren't exempt. Despite rising infrastructure expenses, experts say the cost of using AI is still dropping fast. Research from Epoch AI shows that the computing power needed for the same performance level is falling dramatically each year, thanks to smarter algorithms and better hardware. So, while building AI systems might cost more in the short term, using them could become cheaper for consumers. In short, the tariffs risk raising barriers for U.S. AI development—both financially and strategically—even if the long-term impact remains uncertain. Enterprises like Thumzup Media Corp. (NASDAQ: TZUP) that leverage AI solutions in their service suite will be hoping that the trade war doesn't impose unjustifiable extra costs to their business model.

Thumzup Media Corp. (NASDAQ: TZUP) is at the forefront of modernizing the social media branding and marketing industry with its unique platform designed to connect advertisers directly with everyday social media users. The company’s mission is to empower individuals by turning their authentic social media activity into a monetizable asset while providing brands with cost-effective and impactful advertising solutions.

Through its flagship Thumzup platform, the company offers a seamless system where users post about participating advertisers and receive cash payments via Venmo or PayPal. Thumzup recently announced plans to integrate bitcoin as an additional payment option, expanding accessibility for gig economy workers.

By prioritizing accessibility and transparency, Thumzup is redefining traditional marketing strategies with an inclusive, user-driven approach. It is leveraging its scalable technology to disrupt the status quo, offering a win-win ecosystem for advertisers and users alike.

The company is headquartered in Los Angeles, California.

Products

Thumzup’s key offering, the Thumzup platform, features two integrated components: a sophisticated advertiser dashboard and an intuitive consumer-facing app. The advertiser dashboard provides companies with tools to design, manage, and analyze campaigns.

On the consumer side, the Thumzup app allows users to participate in campaigns by posting approved content to their social media accounts. In exchange, users receive direct cash rewards.

Recent enhancements to the platform include the launch of video capabilities, enabling integration with Instagram Reels. This update allows advertisers to tap into the growing popularity of short-form video content, broadening campaign possibilities.

The platform not only incentivizes users but also delivers authentic, relatable content for advertisers, bridging the gap between grassroots engagement and effective campaign management.

Market Opportunity

The global social media advertising market is projected to reach $219.8 billion in 2024, with an expected annual growth rate of 3.86%, resulting in a market volume of $255.8 billion by 2028, according to Statista. Thumzup targets the intersection of this growth with the rise of micro-influencers and everyday social media users, a segment that remains largely untapped in the advertising ecosystem.

In October 2024, Thumzup achieved 202% year-over-year growth in advertisers on its proprietary platform, demonstrating significant traction and scalability. With plans for further expansion in both advertiser partnerships and user engagement, the company is well-positioned to capitalize on the growing demand for authentic and trust-building marketing strategies. As Thumzup integrates innovative features like video support and continues its geographic expansion, it is poised to capture a larger share of the rapidly growing social media advertising market.

Leadership Team

Robert Steele, Founder and Chief Executive Officer of Thumzup, has over 25 years of experience as a technologist and entrepreneur. He has successfully launched multiple companies, including iBrite, a pioneer in mobile software development. Mr. Steele’s leadership and innovative vision drive Thumzup’s mission to democratize the social media marketing industry.

Robert Haag, Director of Thumzup, is the Managing Member of Westside Strategic Partners LLC and a Managing Director at IRTH Communications. With decades of experience in financial communications, investment, and corporate strategy, Mr. Haag provides critical guidance on strategic initiatives and business growth.

Dr. Joanna Massey, member of the company’s Board of Advisors, brings over 25 years of executive experience with Fortune 500 companies and startups to Thumzup. She has held senior roles in communications at Lions Gate Entertainment and CBS Corporation. Dr. Massey leverages her expertise to support Thumzup’s growth strategy.

Thumzup Media Corp. (NASDAQ: TZUP), closed Friday's trading session at $4.54, up 2.2523%, on 93,040 volume with 00 trades. The average volume for the last 3 months is 132,460 and the stock's 52-week low/high is $2.02/$7.89.

Recent News

• Thumzup Media Corp. (NASDAQ: TZUP) - TechMediaBreaks - Thumzup Media Corp.'s (NASDAQ: TZUP) Dynamic Platform Driving Connection Between Brands, Consumers
• How Trump's New Tariffs Could Increase AI Development Costs
• Thumzup Media Corp. (NASDAQ: TZUP) Launches Patent-Pending Lifestyle AI Agent Marketplace to Disrupt Multi-Billion Dollar Marketing Sector

Calidi Biotherapeutics Inc. (NYSE American: CLDI)

The QualityStocks Daily Newsletter would like to spotlight Calidi Biotherapeutics Inc. (NYSE American: CLDI).

Approximately 65% of patients diagnosed with melanoma are unresponsive to immunotherapy. New research suggests that blocking the HPGDS enzyme can be a viable way to improve patients' response to immunotherapy since the activity of this enzyme contributes to immunotherapy resistance. This approach can also increase immunotherapy response in other types of cancer with similar attributes to those of melanoma. Over the last 10 years, significant advances have been made in leveraging immunotherapy to treat melanoma and other cancers. However, more than half (65%) of melanoma patients don't respond to immunotherapy. TAMs (tumor-associated macrophages) play a major role in this immunotherapy resistance since they hinder immune function and consequently promote the growth of tumors and their metastasis. This research suggests that melanoma and other such cancers may be better treated through interventions that block the PGD2 receptors (the receptor where the HPDGS gene is expressed) or those designed to block the HPDGS gene. Given that this research was preclinical, its findings can only hold concrete promise if they are replicated in clinical studies. There's still plenty to do before this new treatment approach can be tested on human subjects. In the meantime, immune-oncology companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI) that already have new treatments undergoing clinical trials could offer hope to melanoma patients in need of treatments that can deliver the clinical outcomes they seek.

Calidi Biotherapeutics Inc. (NYSE American: CLDI) is a clinical-stage immuno-oncology company pioneering proprietary technology that empowers the immune system to combat cancer. Calidi’s innovative, off-the-shelf cell-based platforms use allogeneic stem cells to deliver potent oncolytic viruses (OVs) across multiple oncology indications, including high-grade glioma (brain cancers) and solid tumors. In addition, Calidi has presented a breakthrough systemic technology, RTNova, which utilizes an exteracellular enveloped virotherapy. RTNova is pre-clinical and has been extremely well-received by market analysts and large-cap biopharma – opening the door for potential collaboration.

These cell-based platforms are engineered to protect, amplify, and enhance the efficacy of oncolytic viruses, resulting in improved patient safety and potentially advancing treatment outcomes for metastatic disease. By employing a dual approach that combines OV delivery with immune activation, Calidi’s therapies aim to not only treat but potentially prevent the spread of metastatic cancers.

The company’s development pipeline leverages this technology to address pressing needs in cancers such as glioblastoma (brain cancer), metastatic melanoma, triple-negative breast cancer, head & neck cancer, and lung cancer. Calidi’s approach has shown early signals of efficacy and safety, establishing it as a distinctive player in the growing OV market, which is projected to increase significantly in value over the next decade.

Calidi is headquartered in San Diego, California.

Products

Calidi’s product pipeline includes advanced cell-based platforms targeting a variety of oncology indications, each designed to harness the power of oncolytic virotherapy for improved cancer treatment outcomes.

• NeuroNova (CLD-101): A platform designed for treating high-grade gliomas (HGG), NeuroNova employs neuronal stem cells combined with an engineered adenovirus (CRAD-s-Pk7) to selectively target glioma cells. After a successful Phase 1 safety study in newly diagnosed HGG, NeuroNova has now progressed into Phase 1/1b trials for recurrent cases. FDA clearance for a Phase 1b/2 trial at Northwestern University was received in September 2024, with patient enrollment expected to begin in Q1 2025. This trial will utilize multiple-dose intracerebral administration to maximize safety and efficacy in newly diagnosed HGG patients.
• SuperNova (CLD-201): Built on Calidi’s foundational technology, SuperNova utilizes an engineered Vaccinia virus (CAL1) delivered via allogeneic adipose-derived mesenchymal stem cells to target advanced solid tumors, including head & neck, triple-negative breast cancer, and soft tissue sarcomas. Early studies with autologous stem cells demonstrated both safety and promising efficacy, and Calidi plans to begin a Phase 1 trial with multiple dose regimens for SuperNova in the coming months.
• RTNova (CLD-400): Calidi’s systemic delivery platform for lung and metastatic cancers, RTNova employs an extracellular enveloped virotherapy (envRT-01) technology for intravenous (IV) administration, simplifying the treatment process and expanding its potential applications. Currently in preclinical stages, RTNova focuses on demonstrating efficacy and safety through systemic administration. A clinical trial targeting metastatic lung cancer is anticipated for Q2 2026, using a single-arm monotherapy with dose escalation. Calidi has partnered with SIGA Technologies (NASDAQ: SIGA) to support the development of this program.

Market Opportunity

The global oncology drugs market was valued at $201.75 billion in 2023 and is projected to grow to $518.25 billion by 2032, with a CAGR of 11.3%. The oncolytic virotherapy market in particular is growing rapidly, driven by increasing approval rates and significant unmet needs.

The market for OV treatments is expected to expand from one approved product generating $150 million in the U.S. in 2021 to 6-8 approved therapies generating $2.4 billion by 2030. As a leader in OV technology, Calidi is well-positioned to address these high-demand areas in oncology.

Alongside global trends, the American Cancer Society projects nearly two million new cancer diagnoses in the U.S. in 2024, reflecting a 28% increase since 2010. This underscores the urgent need for novel therapies that not only treat disease progression but also enhance patient quality of life, reinforcing the demand for Calidi’s innovative approaches.

Management Team

Allan Camaisa, CEO, Chairman, and co-founder, is a seasoned leader with extensive experience in scaling businesses to successful exits. Mr. Camaisa previously led High Technology Solutions, growing it from two employees to over 500 with $50 million in revenue. He also served as CEO of Parallel6 Inc. and is a U.S. Naval Academy graduate with further studies at Harvard Business School.

Antonio Santidrian, Ph.D., Chief Scientific Officer, leads all research and development initiatives at Calidi and is the coinventor of the company’s CLD-201 (Supernova) and CLD-400 (RTNova) platforms. Since joining Calidi in 2015, he has applied his 20+ years of expertise in academia and biotech, focusing on anti-cancer translational research, to drive the company’s innovative drug pipeline. Before Calidi, Dr. Santidrian led translational studies at The Scripps Research Institute, advancing treatments for breast cancer metastasis, and contributed to the development of ACADRA for chronic lymphocytic leukemia (CLL) at the University of Barcelona, Spain.

Boris Minev, M.D., President of Medical and Scientific Affairs, is a renowned physician-scientist with expertise in Immuno-Oncology, stem cell biology, and oncolytic viruses. Previously, Dr. Minev served as Director of Immunotherapy and Translational Oncology at Genelux Corporation and remains an adjunct professor at the Moores UCSD Cancer Center. His background includes research at the National Cancer Institute.

Andrew Jackson, CFO, has held executive finance roles with experience in biotech and clinical-stage companies, including Eterna Therapeutics and Ra Medical Systems. Mr. Jackson holds an MSBA in Finance from San Diego State University and a BSB in Accounting from the University of Minnesota.

Calidi Biotherapeutics Inc. (NYSE American: CLDI), closed Friday's trading session at $0.44, up 7.8431%, on 168,476 volume with 00 trades. The average volume for the last 3 months is 412,067 and the stock's 52-week low/high is $0.35/$7.4.

Recent News

• Calidi Biotherapeutics Inc. (NYSE American: CLDI) - InvestorNewsBreaks - Calidi Biotherapeutics Inc. (NYSE American: CLDI) Appoints Oncology Expert Dr. Guy Travis Clifton as Chief Medical Officer
• BioMedNewsBreaks - Calidi Biotherapeutics Inc. (NYSE American: CLDI) Advances Cancer Platforms, Reports Narrowed Loss for Q4 2024
• InvestorNewsBreaks - Calidi Biotherapeutics Inc. (NYSE American: CLDI) Closes $3.9 Million Offering to Advance Immunotherapy Programs

Torr Metals Inc. (TSX.V: TMET)

The QualityStocks Daily Newsletter would like to spotlightFathom Torr Metals Inc. (TSX.V: TMET) .

Torr Metals operates in well-endowed mining regions, surrounded by major players like Teck's Highland Valley Copper and Copper Mountain Mining

Projects are strategically located near major highways and existing infrastructure, reducing exploration costs and improving logistics

Recently announced Kolos expansion with optioning of drill-permitted Bertha Property, per latest press release

Nine new geophysical anomalies discovered at Filion Project

Leveraging Established Mining Districts for Growth

Torr Metals (TSX-V: TMET) has set itself apart in the junior mining sector by strategically positioning its projects within prolific mining districts. By surrounding itself with major industry players and existing infrastructure, the company maximizes its chances of exploration success while minimizing logistical challenges and costs, as CEO Malcolm Dorsey recently explained in an interview: ( ibn.fm/SdV3J ).

Torr Metals Inc. (TSX.V: TMET) operates as a mineral exploration company focusing on the identification, acquisition, and advancement of mineral properties. With full 100% ownership of over 1,000 square kilometers of gold and copper projects strategically positioned in premier low-cost mining jurisdictions, Torr is poised for substantial returns across various promising regions.

The company’s extensive portfolio encompasses multiple district-scale projects, including the Filion Gold Project in northern Ontario, the Kolos Copper-Gold Project in south-central British Columbia, and the Latham Copper-Gold Project in northern British Columbia. These projects are all located in prolific mining regions with paved highway access, robust support infrastructure, and favorable geological conditions offering significant potential for new discoveries.

Headquartered in Vancouver, British Columbia, Torr Metals is ideally situated to leverage its expertise and resources for continued exploration and growth.

Projects

Kolos Copper-Gold Project

Situated within British Columbia’s prime copper-producing belt, the 140-square-kilometer Kolos Copper-Gold Project exhibits Nicola Belt geology similar to notable porphyry mines, including Copper Mountain and Highland Valley, respectively situated 106 kilometers to the south and 30 kilometers to the northwest.

With field operations based in the nearby city of Merritt and year-round access provided via Highway 5, the Kolos Project showcases substantial discovery upside potential with five defined large-scale copper-gold-molybdenum anomalies untested by drilling.

Torr Metals’ primary focus lies in unlocking the potential for major new discoveries at the Kolos Copper-Gold Project, with recent surface geochemical results marking a significant milestone positioning the company as a new key player in the region.

Filion Gold Project

The 261-square-kilometer Filion Project is situated within a largely unexplored greenstone belt where gold was initially discovered in the 1930s. With a comparable geological setting to regional orogenic gold deposits and multiple newly identified and undrilled gold trends in surficial geochemistry, the Filion Project holds significant district-scale exploration promise.

The Filion Project benefits from unparalleled infrastructure access, with direct drive-on access from the Trans-Canada Highway, as well as a regional railway and power grid four kilometers to the south. Additionally, the nearby town of Kapuskasing, with a population of 8,300, provides essential support services.

This strategic positioning ensures the Filion Project’s viability for cost-effective, year-round operations in an area poised for untapped discovery potential.

Latham Copper-Gold Project

Situated in British Columbia’s renowned Golden Triangle, the Latham Project spans a vast 689-square-kilometer district, offering immense potential for multiple major discoveries. Accessible year-round via Highway 37, just 20 kilometers south of the town of Dease Lake, the site is strategically located amidst established mining infrastructure, including the active Red Chris mine to the southeast and upcoming major porphyry projects at Schaft Creek and Galore Creek along-trend to the southwest.

Highlighted by the Gnat Pass copper-gold porphyry deposit dating back to the 1960s, the Latham Project presents a compelling opportunity for significant expansion and potential discovery. A non-compliant indicated resource at the Gnat Pass deposit includes 33 million tonnes at 0.39% copper, open beyond 200 meters vertical depth, alongside six drill-ready kilometer-scale copper-gold exploration targets.

Moreover, the Latham Project’s appeal corresponds to the region being an attractive destination for major asset acquisitions and takeovers. Recent transactions within a 40-kilometer radius include Newmont’s 2021 acquisition of the Saddle North copper-gold porphyry deposit for $311 million and Newcrest’s investment in the Red Chris copper-gold porphyry deposit in 2019 for $804 million, underscoring industry acknowledgment of the region’s potential.

Market Opportunity

The World Gold Council, the industry association for the world’s gold producers, estimated in 2023 that the physical financial gold market, which is made up of bars, coins, gold ETFs and central bank reserves, is worth nearly $5 trillion.

The council reports that gold mine production adds approximately 3,500 tons of the precious metal to the world’s supply annually, equivalent to about 2% growth. This historical scarcity and relatively slow production of new supply, as compared to other commodities, is a primary reason gold has retained its value for millennia, according to the council.

Likewise, a report from Acumen Research and Consulting, a global provider of market intelligence and consulting services, valued the global copper market at $304.1 billion in 2022 and forecast that it will reach a market size of $496.8 billion by 2032, growing at a CAGR of 5.1% over the forecast period.

The report identifies a growing demand for copper in the electronics industry, as well as an expanding copper supply due to increasing production from existing mines and the rising number of mine development projects in developing nations, as driving factors in the rising value of the copper market.

Management Team

Malcolm Dorsey, P.Geo., is President, CEO and Director of Torr Metals. He brings over a decade of expertise as a seasoned exploration geologist and project developer, having been pivotal in driving the success of numerous diverse projects across North, Central, and South America. His comprehensive background spans early-stage exploration through to resource development and project acquisitions. His academic credentials include an M.Sc. in Geology and Geophysics from the University of Calgary, where his research characterized the district-scale structural influences affecting copper and gold mineralizing events in western British Columbia. Prior to his current role, he served as Senior Geologist for Benchmark Metals, where his contributions were instrumental in advancing the company’s gold equivalent resource from approximately 80,000 ounces to a maiden resource estimate of 2.92 million ounces.

John Williamson, P. Geol., is Chairman and Director of Torr Metals. He is a mining executive and investor with more than 30 years of experience as a founder, promoter and leader in the formation, financing and operation of private and public companies with exploration and mining interests worldwide. On more than one occasion his team’s efforts have been recognized for excellence by being named to the TSX Venture 50. He holds a B.Sc. in Geology and is a registered Professional Geologist (P.Geol.) with the Association of Professional Engineers and Geoscientists (APEGA) and the Geological Association of Canada.

Torr Metals Inc. (TSX.V: TMET), closed Friday's trading session at $22.34, up 2.9019%, on 12 volume with 00 trades. The average volume for the last 3 months is 748 and the stock's 52-week low/high is $20.9045/$31.9.

Recent News

• Torr Metals Inc. (TSX.V: TMET) - Torr Metals Inc. (TSX.V: TMET): Strategic Exploration in Established Mining Districts
• Gold Climbs to New High as Tariff, Inflation Fears Drive Markets
• Copper Prices Surge to Record Highs as Tariff Anxiety Spooks Markets

Nightfood Holdings Inc. (OTCQB: NGTF)

The QualityStocks Daily Newsletter would like to spotlight Nightfood Holdings Inc. (OTCQB: NGTF).

Nightfood Holdings (OTCQB: NGTF) announced its feature in a new editorial by NetworkNewsWire ("NNW"), part of the IBN (InvestorBrandNetwork) Dynamic Brand Portfolio. The article explores how AI-powered service robots are reshaping hospitality by addressing labor shortages and enhancing guest experiences. With a leadership team that has managed over 130 hotels and developed more than 50 properties, Nightfood brings deep operational insight to the table, enabling it to adopt and implement advanced robotics solutions with speed and precision across its hospitality footprint.

To view the full press release, visit https://ibn.fm/dlXGU

Nightfood Holdings Inc. (OTCQB: NGTF) is a hospitality technology and asset acquisition company revolutionizing hotel operations through AI-driven service robotics and strategic property acquisitions. By integrating advanced automation solutions with high-value hospitality assets, NGTF is setting a new standard for operational efficiency, cost reduction, and labor optimization in the hospitality industry.

With a focus on Robotics-as-a-Service (RaaS) and hotel ownership, NGTF is uniquely positioned at the intersection of technology and real estate, creating scalable, revenue-generating solutions that drive the widespread adoption of automation in the hospitality sector.

Operations

Nightfood Holdings is focused on two core business areas:

• Hotel Acquisitions & Operations – NGTF is acquiring a portfolio of independent hospitality properties, spanning various market segments from midscale to luxury. These hotels serve as real-world testbeds for automation technologies, allowing NGTF to refine its RaaS solutions before deploying them at scale.
• Robotics-as-a-Service (RaaS) for Hospitality – NGTF provides subscription-based, AI-driven robotic automation, designed to optimize hotel operations. By deploying standardized automation solutions, NGTF helps hotels reduce costs, improve labor efficiency, and enhance guest experiences.

Through this fully integrated model, NGTF ensures that its robotics solutions are tested, optimized, and proven profitable before expanding to third-party hotel operators.

Market Opportunity

The demand for automation in hospitality is accelerating, driven by labor shortages, rising costs, and increased competition. NGTF is positioned to capitalize on this shift through its combined hotel ownership and RaaS strategy.

• Total Addressable Market (TAM): The global service robotics market is projected to reach approximately $107.75 billion by 2030, driven by widespread adoption across industries including hospitality, according to Research and Markets.
• Serviceable Available Market (SAM): The global smart hospitality market, which includes AI and automation technologies for hotels, is projected to reach $186.10 billion by 2032, according to SNS Insider.
• Competitive Positioning: NGTF’s unique real estate + automation model allows it to implement cost-saving robotics solutions in real-world environments before expanding adoption across the industry.

Industry Impact: The Future of Smart Hotels

NGTF is at the forefront of next-generation hospitality automation, transforming how hotels operate. By combining AI-powered service robotics with real estate acquisitions, NGTF is pioneering the transition to smart, highly efficient hotel environments.

Hotels acquired by NGTF serve as testing grounds for robotics deployment, allowing the company to continuously refine its automation solutions. The biggest industry benefits include:

• Cost Savings for Hotel Operators – Reducing labor costs and improving operational efficiency.
• Scalability & Standardization – Offering a streamlined, subscription-based RaaS model for seamless automation adoption.
• Industry Leadership in Hotel Robotics – Driving the transformation of hospitality with AI-powered automation solutions.

Future Vision & Growth Strategy

Over the next three to five years, NGTF is committed to scaling both its hotel portfolio and RaaS adoption. By refining and optimizing its automation technologies in its own properties, NGTF will continue deploying RaaS to third-party hotel operators, positioning itself as a leader in next-generation hospitality automation.

Through strategic acquisitions and AI-driven solutions, NGTF is defining the future of smart hotels—delivering cost-efficient, scalable automation that reshapes the hospitality landscape.

Team Expertise as a Strategic Advantage

In addition to technology and real estate, NGTF’s most powerful asset is its team. The company’s leadership and operating partners bring deep expertise in both hospitality and food service, having collectively developed over 50 properties, managed more than 130 hotels, and supported more than 6,000 quick-service restaurants.

This wealth of experience enables NGTF to execute its automation and acquisition strategy with operational discipline, industry insight, and scale—further strengthening its position in next-generation hospitality.

Nightfood Holdings Inc. (OTCQB: NGTF), closed Friday's trading session at $0.0563, up 50.1333%, on 1,729,955 volume with 00 trades. The average volume for the last 3 months is 1,793,240 and the stock's 52-week low/high is $0.0053/$0.0563.

Recent News

• Nightfood Holdings Inc. (OTCQB: NGTF) - AINewsBreaks - Nightfood Holdings Inc. (OTCQB: NGTF) Spotlighted for Integrating AI Robotics in Hospitality Operations
• InvestorNewsBreaks - Nightfood Holdings Inc. (OTCQB: NGTF) Featured in Editorial Highlighting AI-Driven Hospitality Innovation
• InvestorNewsBreaks - Nightfood Holdings Inc. (OTCQB: NGTF) Signs LOI to Acquire Victorville Hotel as Flagship AI-Powered Property

Nutriband Inc. (NASDAQ: NTRB)

The QualityStocks Daily Newsletter would like to spotlight Nutriband Inc. (NASDAQ: NTRB).

Nutriband (NASDAQ: NTRB) , a developer of prescription transdermal pharmaceutical products, has been granted a patent in Macao for its AVERSA abuse-deterrent transdermal technology. The patent, titled "Abuse and Misuse Deterrent Transdermal Systems," was granted on Feb. 11 and recorded in Macao's Official Bulletin on Mar. 5. This adds to Nutriband's global IP portfolio, with coverage now spanning 46 countries and both SARs of China. AVERSA is designed to reduce abuse, diversion and accidental exposure of transdermal drugs like opioids. Nutriband is advancing development of AVERSA Fentanyl with partner Kindeva Drug Delivery, aiming to commercialize the world's first abuse-deterrent fentanyl patch with projected peak U.S. sales of $80 million to $200 million. To view the full press release, visit https://ibn.fm/dfThG

Nutriband Inc. (NASDAQ: NTRB) is engaged in the development of a portfolio of transdermal pharmaceutical products. The company’s AVERSA™ technology can be incorporated into any transdermal patch and includes aversive agents to prevent abuse, diversion, misuse and accidental exposure to drugs with abuse potential, specifically opioids.

AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to patients who need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, Canada, Mexico, Australia, and China, with recent extensions into Macao.

The company’s business model is to apply its transdermal technology to existing FDA-approved drugs with a goal of improving safety, efficacy and patient comfort while qualifying for a limited-development regulatory pathway that reduces the number of clinical trials required for approval of new drugs.

Nutriband has three subsidiaries, including 4P Therapeutics, its clinical and regulatory subsidiary; Pocono Pharmaceutical, a contract manufacturer for a wide range of clients; and Active Intelligence, a developer of sports recovery products. This ownership of manufacturing and clinical development capabilities drastically reduces costs for AVERSA and other technologies.

In April 2024, Nutriband announced that the company had been engaged by and received a first order from Fit For Life Group, a major brand license holder. A fully executed supplier agreement is expected to follow. Nutriband’s wholly owned Active Intelligence subsidiary will act as manufacturer.

In February 2025, the company formalized its product development partnership with Kindeva Drug Delivery through a long-term exclusive agreement. The collaboration supports the commercial pathway for AVERSA Fentanyl by leveraging Kindeva’s FDA-approved transdermal fentanyl patch system.

The company is headquartered in Orlando, Florida.

Products

Nutriband’s lead product candidate is AVERSA Fentanyl, an abuse-deterrent fentanyl transdermal patch. The company announced in March 2024 that it will submit a New Drug Application to the U.S. Food and Drug Administration seeking approval to market AVERSA Fentanyl. In subsequent updates, Nutriband confirmed that the NDA submission remains the company’s primary focus and is backed by a strong cash position.

Nutriband has partnered with Kindeva Drug Delivery, a leading global contract development and manufacturing organization, to incorporate Nutriband’s AVERSA abuse-deterrent transdermal technology into Kindeva’s FDA-approved transdermal fentanyl patch system. Because Nutriband’s abuse-deterrent technology is incorporated into the fentanyl patch but is physically separate from and does not come in contact with the drug layer, the clinical trials typically needed to demonstrate safety and efficacy for a new drug formulation would not be required.

In support of this commercialization strategy, Nutriband closed an $8.4 million private placement in April 2024 to fund development activities related to AVERSA Fentanyl. The company also licensed Bitrex®, a widely used aversive agent, to enhance the deterrent profile of its patch formulation.

AVERSA Fentanyl has the potential to be the first and only abuse deterrent patch approved anywhere in the world. The company plans to seek an expedited review by the FDA, as has been granted for certain abuse-deterrent oral opioid products, which shortens the regulatory review period to six months from the conventional 10-month FDA review cycle for NDAs.

Nutriband’s AVERSA product development pipeline also includes abuse deterrent versions of currently approved and marketed transdermal patches containing buprenorphine, an opioid used to treat opioid use disorder, and methylphenidate, a central nervous system stimulant used in the treatment of attention deficit hyperactivity disorder (ADHD). Both are labeled with FDA-required warnings for the risk of abuse and misuse, as well as warnings against accidental exposure.

Market Opportunity

Nutriband cites a market analysis report from Boston-based Health Advances, a healthcare and life sciences consulting firm. According to the report, upon FDA approval, AVERSA Fentanyl has the potential to reach peak annual sales of $200 million in the U.S.

The company further states that, should non-abuse-deterrent transdermal fentanyl products lose FDA marketing approval, AVERSA Fentanyl would have greater pricing flexibility and would have the potential to generate more than $500 million in annual revenue.

Management Team

Gareth Sheridan is Co-Founder and CEO of Nutriband. He was Ireland’s ‘Young Entrepreneur of the Year’ in 2014 for establishing Nutriband. He has worked as a Business Mentor with 100 Minds, a social enterprise that brings together some of Ireland’s top college students and connects them with a cause to achieve large charitable goals. He received a B.Sc. in Business and Management from Dublin Institute of Technology.

Serguei Melnik is Co-Founder and President of Nutriband. He has been involved in general business consulting for companies in the U.S. financial markets and setting up legal and financial frameworks for operations of foreign companies in the U.S. He previously was the COO of Florida-based Asconi Corporation. He also was a lawyer in the Department of Foreign Affairs, JSC Bank “Inteprinzbanca,” in Chisinau, Moldova, and prior to that practiced law in Moldova. He is fluent in four languages.

Jeff Patrick, Pharm.D., is Chief Scientific Officer of Nutriband. He currently serves as Director of the Drug Development Institute at the Ohio State University Comprehensive Cancer Center. His prior roles included Global Vice President at Mallinckrodt Pharmaceuticals Inc.; and roles at Dyax, Myogen/Gilead, Actelion and Sanofi-Synthelabo Inc. He was a clinical pharmacist at the University of Tennessee Medical Center and a clinical assistant professor of pharmacy at the University of Tennessee College of Pharmacy.

Gerald Goodman is CFO of Nutriband. He is a certified public accountant with his own firm, Gerald Goodman CPA. He also practiced with Madsen & Associates, CPAs, and was a partner in the accounting firm of Wiener, Goodman & Company. He is also a director of Lifestyle Medical Network Inc., which provides management services to healthcare providers. He is a graduate of Pennsylvania State University, where he received a bachelor’s degree in accounting.

Nutriband Inc. (NASDAQ: NTRB), closed Friday's trading session at $4.72, up 0%, on 10,827 volume with 00 trades. The average volume for the last 3 months is 18,595 and the stock's 52-week low/high is $3.2/$11.78.

Recent News

• Nutriband Inc. (NASDAQ: NTRB) - InvestorNewsBreaks - Nutriband Inc. (NASDAQ: NTRB) Secures Patent in Macao for AVERSA Abuse-Deterrent Technology
• BioMedNewsBreaks - Nutriband Inc. (NASDAQ: NTRB) Signs Partnership Deal With Charlotte FC to Boost Brand Visibility 
• InvestorNewsBreaks - Nutriband Inc. (NASDAQ: NTRB) Schedules Live Investor Webinar, Q&A Session

FAVO Capital Inc. (OTC: FAVO)

The QualityStocks Daily Newsletter would like to spotlight FAVO Capital Inc. (NASDAQ: FAVO).

FAVO Capital (OTC: FAVO) is strategically positioned to capitalize on increasing demand for alternative lending solutions as traditional banking institutions continue to tighten their lending criteria. The industry shift is fueling significant growth in the private credit sector, with projections signaling that the market could surpass $1.5 trillion this year. A recent article highlights the opportunity ahead for FAVO Capital, indicating the company "is at the forefront of this transformation, employing a strategic approach that balances risk and reward while capitalizing on high-growth opportunities… FAVO Capital has carved a niche for itself by recognizing the immense potential of alternative lending markets and private credit solutions. With traditional lenders often unable to meet the needs of small and medium-sized enterprises (‘SMEs'), alternative lending platforms have stepped in to bridge the gap, offering innovative financing options that cater to the diverse needs of businesses." To view the full article, visit https://ibn.fm/SHiMi

FAVO Capital Inc. (OTC: FAVO) is redefining the private credit and alternative lending industry through a strategic redevelopment of its operations and offerings. With a focus on leveraging financial technology and a client-centric approach, FAVO Capital empowers small to medium-sized businesses with fast, flexible, and reliable access to capital, bridging the gap left by traditional financial institutions.

Empowering Businesses, Redefining Private Credit

As part of its strategy to uplist to Nasdaq, FAVO Capital is enhancing its technology platform, operational scalability, and market positioning to meet higher regulatory standards and attract institutional investors. Headquartered in Fort Lauderdale, Florida, FAVO employs over 120 professionals across five global offices, delivering sustainable growth and value for clients and shareholders alike.

Products and Services

• Proprietary Lending Platform and Mobile App (In Development): FAVO Capital is in the early stages of developing an advanced digital platform designed to enhance client engagement and streamline funding processes. This platform will eventually allow businesses to apply for funding products, track progress, and manage repayment efficiencies. A complementary mobile app is also being planned to provide real-time insights and tailored recommendations, laying the groundwork for an improved borrower experience.
• Fintech-Driven Lending Solutions: FAVO Capital is exploring proprietary and third-party technology tools, including advanced analytics and algorithms, to enhance decision-making speed and reliability in the lending process.
• Flexible Financing Options: FAVO specializes in structuring customized capital solutions tailored to the diverse needs of small business owners, offering scalable and adaptable products that evolve with changing market conditions.

Market Opportunity

The private credit market is experiencing exponential growth as traditional banks reduce their focus on small business lending. According to industry reports, the global private credit market is projected to surpass $1.5 trillion by 2025, driven by increasing demand for alternative financing options.

FAVO Capital is uniquely positioned to capture market share within this booming sector by leveraging fintech innovation to meet the needs of underserved small businesses. With a focus on efficiency, speed, and client satisfaction, FAVO addresses critical gaps in the financial ecosystem while building a platform for long-term growth.

Recent Highlights

• Fintech Innovation: Initial investments in app development and analytics lay the groundwork for future operational efficiency and improved borrower experience.
• Operational Scale: A global footprint with over 120 employees combines the agility of a local lender with the reach of an international financial institution.
• Proven Growth: FAVO’s technology-driven approach has enabled consistent expansion, solidifying its reputation as a trusted partner for small businesses.

Leadership Team

Vincent Napolitano is a Founder and CEO of FAVO Capital Inc. With over two decades of experience in finance and business development, Vincent has been instrumental in building FAVO Capital into a trusted partner for businesses seeking innovative financial strategies. Prior to founding FAVO Capital, Vincent spent 25 years on Wall Street, holding key positions at prominent firms and developing expertise in structuring complex financial deals. He also served as Chief Investment Officer for multiple special purpose vehicles (SPVs), acquiring private stock in pre-IPO unicorn companies such as Facebook and Twitter.

Shaun Quin is a Founding Member and President of FAVO Capital Inc., overseeing the company’s mission to deliver innovative and efficient private credit solutions to small and medium-sized businesses. With over 20 years of global experience as a partner, investor, and director, Shaun brings a strategic and customer-focused approach to his leadership. His expertise in fostering collaboration, building high-performance cultures, and empowering businesses has positioned FAVO Capital as a trusted leader in private lending.

Vaughan Korte, CFO, brings over 15 years of global financial expertise to his role with FAVO Capital Inc. His track record includes managing financial operations for Adidas across 60 countries with budgets exceeding $500 million. Vaughan’s leadership ensures FAVO Capital remains financially resilient, aligning financial strategy with organizational goals and fostering shareholder value.

Glen Steward, Chief Strategy Officer, is a seasoned entrepreneur with over 28 years of experience in the investment and trading industries. He drives FAVO Capital’s strategic initiatives, ensuring the company remains competitive and agile in a rapidly evolving market. Glen has held directorships and board memberships across Mauritius, South Africa, and the United States. His strategic acumen has been pivotal in integrating the FAVO Group of Companies into FAVO Capital Inc., fueling growth and market leadership.

Advisory Board

Bilal Adam, Accounting & Financial Counsel, is a financial expert with over 20 years of experience, including roles as CEO of Stewards Investment Capital. His insights into bespoke investment solutions, including fixed income, equity, and digital assets, support FAVO Capital’s innovative approach to private credit.

Honorable Earnest Hart, Corporate Governance Counsel, brings decades of legal and governance experience, having served as a New York Supreme Court Judge and COO at Columbia University Medical Center. His guidance ensures FAVO Capital maintains robust corporate governance standards.

Rocco Trotta, Business Leadership and Scalability Counsel, is the co-founder of LiRo-Hill and has decades of experience scaling businesses. His expertise in organizational efficiency and talent development strengthens FAVO Capital’s ability to attract excellence across all aspects of the business.

As FAVO Capital redevelops its operations and prepares for an uplisting to Nasdaq, the company is laying the foundation to redefine private credit with emerging fintech solutions and exceptional leadership. Learn more by visiting investors.favocap.com.

FAVO Capital Inc. (OTC: FAVO), closed Friday's trading session at $0.99, up 0%, on 2,335 volume with 00 trades. The average volume for the last 3 months is 380 and the stock's 52-week low/high is $0.162/$1.08.

Recent News

• FAVO Capital Inc. (OTC: FAVO) - InvestorNewsBreaks - FAVO Capital Inc. (FAVO) Tapping into Growing Private Credit Market
• InvestorNewsBreaks - FAVO Capital Inc. (FAVO) Bringing Key Financing Options Tailored to Unique Dynamics of SMBs
• FAVO Capital Inc. (FAVO) Strengthening Position in Growing Private Credit, Alternative Lending Markets

Adageis

The QualityStocks Daily Newsletter would like to spotlight Adageis

Adageis provides clinics and medical groups with AI-powered tools to track financial outcomes tied to quality care, in profitable shift from fee-for-service to value-based models.

Its system helps decipher complex insurance contracts to maximize reimbursements.

The software helps decipher complex insurance contracts to maximize reimbursements, integrating smoothly with major electronic health record systems to identify high-risk patients and care gaps.

Adageis is continuously working with investors to expand its offerings for a growing list of small and independent practices.

Adageis, a forward-thinking healthcare technology company focused on value-based care solutions, is helping clinics and medical groups measure how their delivery of high-quality care translates into financial return. The company's AI-driven platform enables providers to visualize revenue trends over time, identify where value-based incentives are being earned, and assess the impact of care improvements on the bottom line.

Adageis is positioning as a key player in healthcare financial technology, offering an innovative AI-powered ProActive Care Platform that helps providers transition from fee-for-service to value-based care models. Its Patented Risk Engine ("PRE") enables predictive analytics for optimizing revenue, improving patient outcomes, and simplifying insurance complexities. By seamlessly integrating with widely used systems, the platform delivers an easy-to-use, efficient, and scalable solution for value-based care revenue optimization. With streamlined onboarding, projected growth and funding, Adageis is poised for significant expansion in the healthcare technology space, offering investors a compelling opportunity to participate in the evolving $19.27 billion healthcare AI market. To view the full article, visit https://ibn.fm/CtGdM

Adageis is a healthcare technology company dedicated to revolutionizing patient care through innovative solutions. By integrating artificial intelligence (AI) and machine learning, Adageis addresses inefficiencies in healthcare delivery, enabling providers to enhance patient outcomes and streamline operations. The company focuses on leveraging advanced technology to meet the growing demand for value-based care and quality incentives in the healthcare sector.

With a commitment to innovation and practical solutions, Adageis empowers clinics, healthcare centers, and care networks to implement its ProActive Care Platform without the need for expensive platform changes or extensive staff training. This approach reduces barriers to adoption and helps healthcare organizations maximize their potential in an increasingly complex industry landscape.

Recent collaborations, including its partnership with HealthyU Clinics and integration with AthenaHealth as a marketplace partner, underscore Adageis’s industry relevance and adaptability.

Adageis is headquartered in Mesa, Arizona.

Services

Adageis offers the ProActive Care Platform, an AI-driven solution designed to integrate seamlessly with existing Electronic Medical Records (EMR) systems.

This platform enables healthcare providers to deliver patient-centric care while maximizing reimbursements from quality metrics and value-based contracts. Key features include:

• Predictive Analytics: Utilizes AI to analyze patient data, identifying high-risk individuals and care gaps to improve health outcomes and reduce costs.
• Efficiency and Cost Reduction: Continuously monitors patient health, allowing providers to offer proactive care even outside traditional office visits, thereby enhancing efficiency and lowering expenses.
• Flexible Integration: Compatible with various EMR systems, including AthenaHealth, Cerner, eClinicalWorks, Allscripts, and Epic, facilitating easy adoption without the need for extensive staff training or platform changes.

Market Opportunity

The global AI in healthcare market is experiencing rapid growth, driven by the increasing demand for enhanced efficiency, accuracy, and better patient outcomes. In 2023, the market was valued at approximately $19.27 billion by Grand View Research, and it is projected to grow at a compound annual growth rate of 38.5% from 2024 to 2030. This growth is fueled by the increasing need for solutions that can analyze large datasets, reduce costs, and improve care delivery across the healthcare continuum.

Adageis is well-positioned to capitalize on these trends. Its ProActive Care Platform offers AI-driven predictive analytics and proactive care solutions that align with the industry’s shift toward value-based care. By providing seamless integration with existing EMR systems and focusing on operational efficiency, Adageis enables healthcare providers to meet the demands of a rapidly evolving market.

Leadership Team

Shane Speirs, MD, MBA serves as the company’s CEO. He is a board-certified physician in family and geriatric medicine with extensive experience in healthcare leadership, data modeling, and AI applications in healthcare delivery. He holds an MBA in Healthcare Management from the W.P. Carey School of Business and has a proven track record in managing telehealth and AI-focused healthcare companies.

Bill Jentarra, MBA is the CTO of Adageis, bringing over 25 years of experience in architecting and implementing complex client relationship management (CRM) and business intelligence (BI) solutions across various industries, including healthcare. His expertise encompasses the entire lifecycle of CRM and BI projects, ensuring practical and cost-effective technology applications to solve complex business problems.

Recent News

• Adageis - Adageis Helps Medical Providers Track and Build Revenue Through Efficient Application of Value-Based Care
• InvestorNewsBreaks – Adageis Brings Power of AI to the Frontlines of Healthcare
• Adageis Offers Enhanced Transparency in Insurance Payments for Healthcare Providers

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

A report from CnEVPost.com revealed that domestic electric vehicle sales in China surged by 37% in March. China leads the world in electric vehicle sales thanks to its massive population's demand for electric vehicles, and a fiercely competitive industry that has kept electric cars low cost and affordable for a majority of the population. Compared to drivers in Western countries, Chinese drivers are purchasing new energy vehicles such as plug-in hybrid electric vehicles (PHEV), battery electric vehicles (BEVs), and hydrogen fuel cell cars at an incredibly rapid pace. CnEVPost.com reports that this resulted in a 37% increase in electric vehicle sales in the Asian nation last month. Of the 17.1 million EVs sold worldwide in 2024, analytics firm Rho Motion estimates that 11 million or 64% were delivered to Chinese drivers, increasing China's share of global EV sales by 40% year-over-year. 3 million EVs were delivered to European drivers, the U.S. and Canada bought 1.8 million electric cars, and drivers in other remaining countries purchased 1.3 million EVs in 2023. Automakers like Mullen Automotive Inc. (NASDAQ: MULN) now have to do everything in their power to wrestle market share from Chinese firms in major markets around the world.

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Friday's trading session at $2.18, up 5955.56%, on 4,353,969 volume with 00 trades. The average volume for the last 3 months is 782,531 and the stock's 52-week low/high is $2.02/$4710000.

Recent News

• Mullen Automotive Inc. (NASDAQ: MULN) - China Registers 37% Surge in Domestic EV Sales in March
• InvestorNewsBreaks - Mullen Automotive Inc. (NASDAQ: MULN) Partners With Enpower Greentech to Produce Solid-State Batteries in California
• Chemical-Assisted Water Hydrolysis Could Supercharge Energy Transition

Newton Golf Company Inc. (NASDAQ: NWTG)

The QualityStocks Daily Newsletter would like to spotlight Newton Golf Company Inc. (NASDAQ: NWTG).

Newton Golf Company (NASDAQ: NWTG) is poised for opportunity as a technology-driven innovator in the rapidly growing global golf equipment market. According to Fact.MR, the sector was valued at $18.34 billion last year and is projected to reach $29.3 billion by 2034. Formerly known as Sacks Parente, the company's new brand pays tribute to Sir Isaac Newton, whose groundbreaking discoveries in physics forever changed the world's understanding of motion and force, principles that are fundamental to the game of golf. NWTG's advanced products, from high-performance shafts to next-generation putters, are designed to increase distance and accuracy and promote smooth strokes and a steady tempo. With a focus on innovation and precision engineering, the company continues to push the boundaries of golf technology.

To view the full article, visit https://ibn.fm/Ev3zZ

Newton Golf Company Inc. (NASDAQ: NWTG), a Sacks Parente Company, is a technology-forward golf equipment manufacturer committed to enhancing player performance through innovative design. Since its founding in 2018, the company has developed a growing portfolio of premium golf products, including putters, golf shafts, grips, and related accessories. Its proprietary advancements include the First Vernier Acuity putter, patented Ultra-Low Balance Point (ULBP) technology, weight-forward Center-of-Gravity (CG) design, and ultra-light carbon fiber putter shafts.

As part of its commitment to growth in golf shaft technologies, the company expanded its manufacturing operations in April 2022, opening a dedicated facility in St. Joseph, Missouri. This move reinforced its goal of maintaining high-quality production standards while manufacturing and assembling substantially all of its products in the United States. In addition to golf clubs and accessories, Newton Golf Company is exploring expansion into golf apparel and other product categories.

The company sells its products through multiple channels, including resellers, its direct-to-consumer website, Club Champion retail stores, and distributors in the U.S., Japan, and South Korea. Future expansion may include growth through mergers, acquisitions, or the development of complementary product lines.

Newton Golf Company is headquartered in Camarillo, California.

Products

Newton Golf Company is focused on delivering high-performance golf equipment with a strong emphasis on precision engineering and cutting-edge materials. The company’s key product lines include:

• Newton Motion Golf Shafts: Launched in November 2023, these shafts are engineered with proprietary flex profiles designed for greater distance, reduced dispersion, and optimized performance across swing speeds. The company’s DOT system eliminates traditional shaft flex definitions, making it accessible to all golfers.
• Gravity Putters: Introduced in October 2024, these putters incorporate patented Ultra-Low Balance Point (ULBP) technology to improve stroke consistency and tighten putt dispersion. Manufactured in the U.S., they feature premium materials such as steel, aluminum, titanium alloys, and patented magnesium face plate technology.
• Golf Grips & Accessories: The company continues to innovate in this category, providing golfers with performance-enhancing grips and accessories to complement their clubs.

All Newton Golf Company products are manufactured with strict quality control standards to ensure precision and reliability, reinforcing the brand’s reputation for premium performance.

Market Opportunity

The global golf equipment market was valued at approximately $8 billion in 2022, with the U.S. market accounting for $2.9 billion. The golf club segment dominated the industry, representing 45.7% of total market share. Increasing participation in golf, particularly among younger players and women, is driving demand for high-quality, customizable golf equipment.

Key industry trends supporting growth include:

• The increasing popularity of premium, high-performance golf equipment among both professionals and amateurs.
• A shift toward customization, as golfers seek tailored products that enhance performance.
• A growing interest in golf from younger demographics, with amateur and collegiate golfers being particularly receptive to innovation.

Newton Golf Company’s emphasis on U.S.-based manufacturing provides it with a competitive edge in terms of supply chain efficiency, quality control, and sustainability, further strengthening its position in the market.

Leadership Team

Dr. Greg Campbell, Executive Chairman and Chief Executive Officer, brings nearly 40 years of experience in emerging technologies, product development, and public company leadership. He currently serves as CEO of V-Grid Energy Systems, a California-based company focused on converting agricultural waste into renewable electricity and bio-carbon. He has successfully taken two companies public and previously managed a $1.2 billion P&L as SVP & GM at Lam Research. Campbell holds a Ph.D. in Electrical and Electronics Engineering from UCLA and a BA/MA in Engineering from Cambridge University.

Ryan Stearns, Chief Financial Officer, was appointed in 2024 and oversees financial planning and corporate strategy. He brings expertise in scaling businesses and optimizing financial performance to support the company’s growth.

Newton Golf Company Inc. (NASDAQ: NWTG), closed Friday's trading session at $1.85, up -6.0914%, on 671,199 volume with 00 trades. The average volume for the last 3 months is 7,092,515 and the stock's 52-week low/high is $1.35/$195.

Recent News

• Newton Golf Company Inc. (NASDAQ: NWTG) - InvestorNewsBreaks - Newton Golf Company Inc. (NASDAQ: NWTG) Pushes the Limits of Performance with Advanced Tech
• Newton Golf Company (NASDAQ: NWTG) Elevates Golf Performance with High-Quality Gravity Putters
• Newton Golf Company (NASDAQ: NWTG) Is Focused on Fitted Golf Shafts, Committed to Advancing Players' Performance

Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF)

The QualityStocks Daily Newsletter would like to spotlightFathom Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF).

A couple of weeks ago, the price of copper was soaring as America stockpiled ahead of its recently announced tariffs. Major players like Trafigura and Mercuria even forecasted that prices could hit $12,000 per ton. Following the announcement of the reciprocal tariffs by President Trump though, the red metal's rally reversed into a fully-fledged crash, with investor concerns that the new tariffs will negatively influence global demand for copper increasing. The crash was further fueled by Beijing announcing that it'd levy a 34% tariff on all American imports starting April 10. David Wilson, a strategist at BNP Paribas SA, agrees that the drop may continue in the short term. This opinion is shared by Goldman Sachs, which admits that the current environment could delay the metal's expected shortage in supply. JPMorgan expects America to go into a recession this year. Hopefully, the headwinds facing the copper market are short-lived so that the plans of entities like Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF) aren't overly affected and investor interest remains high.

Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF) is a publicly traded Canadian minerals exploration company focused on exploring high-grade copper and gold deposits in North America. The company owns the Storm Copper Project and the Seal Zinc Deposit in Nunavut, Canada, and is currently exploring the Buckingham Gold Vein and critical metals prospects in central Virginia. Aston Bay is also in the advanced stages of negotiation on other properties with high-grade critical minerals potential in these areas.

The company believes in responsible exploration and carries out its work programs to the highest standards of social responsibility, environmental stewardship and health and safety. Aston Bay cares about leaving a net positive impact on the communities in which it works and engages with local representatives, Indigenous groups and government agencies to build respectful relationships through dialogue and collaborative processes. Depending on the stage of exploration, these efforts may include employment, contracting, training, community benefits and other agreements.

Aston Bay conducts exploration through safe, socially and environmentally responsible and sustainable work practices. The company embeds core values of health and safety throughout its operations by adhering to strict health and safety standards and practices that meet and/or exceed industry standards and government codes and regulations.

The company is headquartered in Toronto.

Projects

Storm Copper

The high-grade Storm Copper Deposit is located 112 kilometers south of the community of Resolute Bay, Nunavut, on western Somerset Island, just south of the past-producing Polaris Pb-Zn Mine. The property comprises 173 contiguous mining claims, including the Storm Copper and Seal Zinc projects, covering an area of approximately 541,795 acres.

The property has good access to established shipping lanes, and the landscape provides favorable conditions for development of roads and a protected deep-water port. Exploration is supported through excellent infrastructure in the nearby hamlet of Resolute Bay.

Aston Bay is partnered with American West Metals (ASX: AW1) at Storm. American West is responsible for all exploration expenditures, having aggressively advanced the project toward production and earned an 80% interest. This affords excellent optionality to the company’s shareholders, as Aston Bay is free carried with no required expenditures until the completion of a bankable feasibility study.

American West recently completed an Australian JORC-compliant Maiden Resource Estimate for Storm; the North American 43-101 compliant resource estimate is expected in Q1 2024. American West is cashed up and plans a multimillion-dollar resource expansion and new discovery drilling program for the summer of 2024.

The Buckingham County Gold Project

The gold-bearing system at the Buckingham County Gold Project in Virginia lies within a belt hosting past producing mines, current gold mines and advanced gold explorations, stretching through Georgia, the Carolinas, Virginia, Nova Scotia and Newfoundland.

Buckingham hosts a “Kirkland Lake-style” high grade gold vein returning values consistently over one ounce gold per ton and is underexplored both at depth and along almost one mile of strike length. These types of veins have excellent ESG qualities, as they are typically mined using a small footprint underground method, with gold extracted using simple and environmentally friendly gravity methods.

Market Opportunity

The World Gold Council, the industry association for the world’s gold producers, estimated in 2023 the physical financial gold market, which is made up of bars, coins, gold ETFs and central bank reserves, is worth nearly $5 trillion. The council reports that gold mine production adds approximately 3,500 tons of the precious metal to the world’s supply annually, equivalent to about 2% growth.

This historical scarcity and relatively slow production of new supply, as compared to other commodities, is a primary reason gold has retained its value for millennia, according to the council.

A report from Acumen Research and Consulting, a global provider of market intelligence and consulting services, valued the global copper market at $304.1 billion in 2022 and forecast that it will reach a market size of $496.8 billion by 2032, growing at a CAGR of 5.1% over the forecast period.

The report identifies a growing demand for copper in the electronics industry, as well as an expanding copper supply due to increasing production from existing mines and the rising number of mine development projects in developing nations, as driving factors in the rising value of the copper market.

Management Team

Thomas Ullrich is CEO and Director of Aston Bay. He has over 30 years of experience in mineral exploration and geoscience. Before joining Aston Bay, he was Chief Geologist North America for Antofagasta Minerals plc, investigating copper potential through extensive property evaluations and management of drill programs in the United States, Mexico and Canada. Prior to that, he was Senior Geologist for Almaden Minerals.

Sofia Harquail handles Investor Relations and Corporate Development at Aston Bay. She has over 15 years of experience in the private and public sectors of the mining industry. Before joining Aston Bay, she worked as a consultant for the Prospectors and Developers Association of Canada and for exempt market dealer Red Cloud Financial Services Inc. Ms. Harquail holds an M.A. from the University of Uppsala in Sweden and received her CPIR designation from the CIRI/Ivey Investor Relations Program. She also sits on the board of the Young Mining Professionals Toronto and is CSC Certified.

Aston Bay has a talented Board of Directors bringing broad experience from across the industry, encompassing resource expansion, mine development, mergers and acquisitions, and mining finance.

Ms. Jessie Liu-Ernsting has over 15 years of experience in the mining industry, spanning capital projects engineering, debt capital markets, private equity and corporate strategy at several firms, including Hudbay Minerals and Resource Capital Funds. She is currently VP Investor Relations and Communications at G Mining Ventures Corp.

Mr. Jeffrey R. Wilson has over 25 years’ experience in the mining industry, having served as a director, officer and advisor of multiple public and private companies in the mineral exploration and mining investment industries. Mr. Wilson is currently President & CEO of Precipitate Gold Corp.

Mr. Gary O’Connor has over 40 years of diverse experience as a mineral exploration and development professional in the management of successful resource projects as well as the evaluation, technical due diligence, and supervision of large mineral exploration and development projects through-out the world. While with Freeport, Mr. O’Connor worked on the due diligence and discovery of a major gold fraud on the Busang gold “deposit” in Kalimantan by Bre-X.

Mr. Mark J. Pryor is a geologist with a 40-year track record of successfully advancing multiple precious metal, copper, coal, REE and Li projects from discovery through to exploitation. He is currently Executive Vice President of the Exploration Division at The Electrum Group.

Aston Bay Holdings Ltd. (OTCQB: ATBHF), closed Friday's trading session at $0.0391, up -9.3859%, on 10,000 volume with 00 trades. The average volume for the last 3 months is 236,910 and the stock's 52-week low/high is $0.03095/$0.107.

Recent News

• Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF) - InvestorNewsBreaks - Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF) Secures Strategic Funding Boost for Storm Copper Project
• Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF) Solidifies Presence in Copper, Silver Markets with Significant Resource Estimate at Storm Copper Project
• Copper Prices Tumble as Markets Dampen After Trump Announces Tariffs

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Friday's trading session at $1.34, up 13.5593%, on 139,503 volume with 00 trades. The average volume for the last 3 months is 311,341 and the stock's 52-week low/high is $0.9901/$800.

Recent News

• CNS Pharmaceuticals Inc. (NASDAQ: CNSP) - Study Uncovers Drivers of Brain Tumor Growth, Could Open New Treatment Approaches
• Pitt Researchers Develop Diagnostic Tool for Profiling Pediatric Brain Cancers
• InvestorNewsBreaks - CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Advances TPI 287 for GBM, Ends 2024 with Strong Cash Position

Soligenix Inc. (NASDAQ: SNGX)

The QualityStocks Daily Newsletter would like to spotlight Soligenix Inc. (NASDAQ: SNGX).

Soligenix Inc. (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases with high unmet medical needs. Operating through two key segments, the company’s Specialized BioTherapeutics division is dedicated to oncology and inflammation therapies, while its Public Health Solutions segment advances vaccines and therapeutics targeting biothreats and infectious diseases.

The company is actively advancing multiple late-stage clinical programs, including HyBryte™ (SGX301), a novel photodynamic therapy for cutaneous T-cell lymphoma (CTCL). Additional candidates in development target psoriasis (SGX302), oral mucositis (SGX942), and Behçet’s disease (SGX945), while its public health efforts focus on heat-stable vaccines for ricin poisoning (RiVax®), Ebola (SuVax™), and Marburg (MarVax™) viruses, that have been supported by non-dilutive government grants and contracts of approximately $60 million to date.

With a diversified pipeline, multiple orphan and fast-track designations, and collaborations with government agencies, Soligenix is uniquely positioned for potential regulatory approvals and commercialization.

The company is headquartered in Princeton, New Jersey.

Pipeline and Development Programs

Specialized BioTherapeutics

Soligenix’s Specialized BioTherapeutics division develops treatments for oncology and inflammatory diseases, focusing on conditions with few or no effective therapeutic options. HyBryte™ (synthetic hypericin) has completed a Phase 3 study for CTCL, demonstrating statistically significant efficacy, and a second confirmatory Phase 3 trial is actively enrolling patients to support potential regulatory submissions worldwide. If approved, it would be the first non-mutagenic photodynamic therapy for early-stage CTCL, addressing an unmet medical need. It has received orphan drug designations in the U.S. and Europe, as well as Fast Track designation in the U.S.

SGX302, a photodynamic therapy based on the same active ingredient as HyBryte™, is in clinical development for mild-to-moderate psoriasis, with positive Phase 1/2 proof-of-concept results, it is actively enrolling patients in a Phase 2a clinical trial.

SGX942, designed to reduce inflammation and tissue damage in oral mucositis associated with cancer treatment, is progressing as a potential first-in-class therapy.
SGX945, targeting aphthous ulcers in Behçet’s disease, is actively enrolling in a Phase 2a clinical trial and has received fast-track designation, highlighting the urgency of developing effective treatments for this rare inflammatory condition.

Public Health Solutions

The company’s Public Health Solutions segment focuses on medical countermeasures for biothreats and emerging infectious diseases, leveraging non-dilutive government funding to advance its programs. RiVax®, a ricin toxin vaccine, has demonstrated strong preclinical and early clinical results and may be eligible for government procurement under the Strategic National Stockpile initiative.

The company’s RiVax®, as well as its vaccine candidates for Ebola and Marburg viruses are based on its proprietary ThermoVax® technology, which stabilizes vaccines for long-term storage without refrigeration. This approach could be transformative in regions where maintaining cold-chain logistics is challenging.

The ongoing development of these vaccines is supported by funding from NIH, BARDA, and DTRA, with the potential for up to three priority review vouchers (PRVs) upon regulatory approval, to be used for future programs or sold. Notably, PRVs have previously sold for roughly $100 million.

Market Opportunity

Soligenix targets markets with significant commercial potential, focusing on rare diseases and biodefense applications. HyBryte™ addresses CTCL, a disease affecting over 68,000 patients across the U.S. and Europe, with a total market opportunity exceeding $250 million. SGX302, the company’s therapy for mild-to-moderate psoriasis, serves a much larger population, as over eight million people in the U.S. are affected by the condition, representing a global market opportunity exceeding $1 billion.

SGX942, developed for oral mucositis in head and neck cancer patients, is aimed at a market worth more than $500 million, while SGX945 for Behçet’s disease serves a niche segment valued at over $200 million worldwide.

In addition to its rare disease programs, Soligenix’s Public Health Solutions division has the potential to generate significant revenue through government procurement contracts. By focusing on both orphan drug markets and government-funded biodefense initiatives, Soligenix has positioned itself for sustained revenue growth through multiple high-value opportunities.

Leadership Team

Christopher J. Schaber, PhD, Chairman, President & CEO, brings to the company more than 35 years of experience in the biopharmaceutical industry. Before joining Soligenix, he held senior and operational leadership roles at Discovery Laboratories, Acute Therapeutics, Ohmeda Pharmaceuticals, The Liposome Company, and Wyeth Ayerst Laboratories. He has extensive expertise in drug development, regulatory affairs, and corporate strategy, positioning him to drive Soligenix’s growth and advancement toward commercialization.

Richard Straube, MD, Chief Medical Officer, has more than 35 years of experience in drug development and clinical research. Prior to joining Soligenix, he held key leadership roles at Stealth Peptides, INO Therapeutics, Ohmeda Pharmaceuticals, and Centocor. Throughout his career, he has played a crucial role in bringing innovative therapies to market, particularly in inflammatory diseases and immunology, making him a valuable asset in advancing Soligenix’s late-stage clinical programs.

Oreola Donini, PhD, Chief Scientific Officer, has more than 20 years of experience in pharmaceutical research and development, with expertise in immunology, inflammation, and rare diseases. Before joining Soligenix, she held leadership positions at Inimex Pharmaceuticals, ESSA Pharma, and Kinetek Pharmaceuticals, where she worked on novel drug discovery and translational medicine. Her experience in preclinical research and product development supports Soligenix’s continued innovation in biopharmaceuticals.

Jonathan Guarino, CPA, CGMA, Chief Financial Officer, has over 25 years of experience in corporate finance and strategic financial planning. Before joining Soligenix, he held financial leadership positions at Hepion Pharmaceuticals, Covance, BlackRock, and Barnes & Noble. His expertise in financial management, accounting, and capital markets plays a critical role in Soligenix’s financial strategy and operational efficiency.

Soligenix Inc. (NASDAQ: SNGX), closed Friday's trading session at $2.175, up 15.0794%, on 49,839 volume with 00 trades. The average volume for the last 3 months is 30,117 and the stock's 52-week low/high is $1.68/$14.9184.

Recent News

• Soligenix Inc. (NASDAQ: SNGX) - Soligenix Inc. (NASDAQ: SNGX) Spotlighted in Recent Zacks Small-Cap Research Report, Earns a $35 Valuation
• Soligenix Inc. (NASDAQ: SNGX) Advances Phase 3 Replication Study for Early-Stage Cutaneous T-Cell Lymphoma Treatment
• BioMedNewsBreaks - Zacks Maintains $35.00 Price Per Share Valuation for Soligenix Inc. (NASDAQ: SNGX) Amid Promising Vaccine and CTCL Therapy Progress